Izvorni znanstveni članak
https://doi.org/10.21857/yvjrdcn3zy
Neoadjuvant radiotherapy and chemotherapy in localy advanced rectal cancer: prospective, randomized phase III study, in colaboration with IAEA, ESTRO and UHC “Sestre milosrdnice"
Ana Fröbe
Jasmina Marić Brozić
Željko Soldić
Ante Bolanča
Mario Zovak
Glenn Jones
Eduardo Rosenblatt
Nikola Đaković
Sažetak
At the Department of Oncology and Nuclear Medicine UHC “Sestre milosrdnice” patients who had advanced rectal cancer were treated with preoperative radiotherapy and chemotherapy, in cooperation with the IAEA and ESTRO. Fifteen patients who met the criteria and signed informed consent were included. Patients were randomized into two groups: Group 1: standard group, neoadjuvant approach (chemotherapy 5-FU / leucovorin concomitantly with radiotherapy (45-50 Gy in 25 fractions); Group 2: short course group, chemotherapy 5-FU / leucovorin with radiotherapy (25 Gy in 5 fractions). The main objectives were to determine the rate of resectability after completion of neoadjuvant therapy and to determine the percentage of local control and overall survival.
Ključne riječi
neoadjuvant therapy; locally advanced rectal cancer
Hrčak ID:
182397
URI
Datum izdavanja:
5.6.2017.
Posjeta: 1.324 *